A study comparing the impact of nebulised dexmedetomidine with nebulised lignocaine on blood pressure on intubation

Randomised trial comparing the efficacy of pre-operative Nebulised Dexmedetomidine with Nebulised Lignocaine in attenuation of hemodynamic pressor response to laryngoscopy and nasotracheal intubation-A Phase II study - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/074659

Enrollment

Registered

2024-10-03

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Dexmedetomidine nebulisation Lignocaine nebulisation: consent followed by randomisation to lignocaine or dexmedetomidine group on the day of surgery, in the preoperative room Interventi

Eligibility

Inclusion criteria

Inclusion criteria: Adults, both male and female, aged above 18years, coming for surgery under general anesthesia needing nasotracheal intubation, classified under ASA 1,2 status

Exclusion criteria

Exclusion criteria: presence of heart block, asa 3-4, drug allergy to propofool, egg, cardiac dysfunction

Design outcomes

Primary

Measure	Time frame
Comparison of the efficacy of nebulised dexmedetomidine with nebulised lignocaine on attenuation of systolic blood pressure in patients undergoing laryngoscopy and nasotracheal intubationTimepoint: before drug administration, induction and 10 minutes after nasotracheal intubation	—

Secondary

Measure	Time frame
the effect of nebulised dexmed/lignocaine on heart rate, BP, sedation score, need for additional drugs to maintain hemoodynamic stability, the mean of the pre induction and post intubation HR, Mean arterial pressure and diastolic bp shall be compared, mean propofol requirement between the 2 groups shall be comparedTimepoint: pre drug, induction and 10 minutes post intubation	—

Countries

India

Contacts

Public ContactDr.Pritha Raj

cancer institute

pritharaj1989@yahoo.co.in09840318716

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026